Navigation Links
Cyberonics Announces Investment In cerbomed GmbH
Date:9/20/2012

HOUSTON, Sept. 20, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced an initial investment of € 2 million in cerbomed GmbH ("cerbomed").  Based in Erlangen, Germany, cerbomed is a privately-held company developing a non-invasive neurostimulation device for the treatment of epilepsy.  The NEMOS® t-VNS device received CE Mark approval for the treatment of epilepsy and depression in 2010 and for pain in 2012 and is now commercially available in Germany and Austria.

The investment in cerbomed can total up to € 5.5 million, subject to the achievement of certain clinical milestones.  Cyberonics is a minority shareholder with certain rights, including representation on cerbomed's advisory board and an exclusive option for worldwide sales and distribution of the NEMOS system for the treatment of epilepsy.  The initial investment will be used to fund cerbomed's current clinical trial in epilepsy in Germany.  Subject to certain conditions, Cyberonics has the option to conduct a trial in the U.S. for the purpose of seeking FDA approval. 

"As a company focused on device solutions for epilepsy, an investment in cerbomed's technology is aligned with our strategic priorities and core expertise," said Dan Moore, Cyberonics' President and Chief Executive Officer.  "We are excited about the opportunity to invest in a technology that may provide more patients with epilepsy another device-based therapeutic option and opportunity for improved quality of life."

Andreas Hartlep, cerbomed's Chief Executive Officer, added, "We are delighted to welcome Cyberonics, the world market leader in vagus nerve stimulation, as our strategic global partner for the epilepsy indication.  We look forward to
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cyberonics To Participate In Upcoming September Investor Conferences
2. Cyberonics To Present At Morgan Stanley 2012 Global Healthcare Conference
3. Cyberonics To Report Fiscal Year 2013 First Quarter Results And Host Conference Call On August 28, 2012
4. ULURU Inc. Announces First Order Of Altrazeal For European Launch
5. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
6. FDAnews announces Third Annual Pharmaceutical Labeling Summit
7. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
8. PRN Physician Recommended Nutriceuticals announces partnership with Dr. Eric Donnenfeld and expansion in the New York City metropolitan area
9. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
10. Specialty Pharmacy Certification Board Announces Inaugural Board of Directors
11. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 Qiming Venture ... to Managing Partner effective immediately. William ... has lead and participated in many Qiming healthcare deals, ... in the Chinese market. Qiming, s success in healthcare ... he has distinguished himself with his outstanding advocacy and ...
(Date:7/1/2015)... 1, 2015 ExeGi Pharma, a company focused ... announced today that it has been granted a product ... Products Directorate (NNHPD) to sell Visbiome™ in ... by Professor Claudio De Simone , MD, PhD ... Professor De Simone recently signed an exclusive agreement with ...
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
Breaking Medicine Technology:Qiming Announces the Promotion of William Hu to Managing Partner 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... As if ... symptom found in a significant number of women: leg pain. Northeast Houston Vein Center ... Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. Many ...
(Date:7/1/2015)... ... ... Trevor L. Williams, DMD holds a Bachelor of Science degree in Biomedical Sciences ... in Microbiology. He graduated from the University of Florida College of Dentistry in 2015 ... and the Academy of General Dentistry. Dr. Williams was born in Tampa and is ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... solution provider of IBM software products, announced today that it has received trademark ... the integration, display and detailed analysis of data from multiple sources providing an ...
(Date:7/1/2015)... Raleigh, NC (PRWEB) , ... July 01, 2015 ... ... Britain’s 2013 mesothelioma compensation law has just published a top ten list they ... on the report. Click here to read it now. , ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Author Francesca Camp wasn’t always a ... her lap, so too did her support of the practice; a terrible car accident years ... her new book, “Do I Need It ? (And What if I Do?): Answers ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... sector providers of social care services face a host ... commitment to expanding personal budgets* in social care. The ... expand personal budgets are outlined in ,The impact of ... This new booklet highlights the views of leading ...
... April 1 Anesiva, Inc. (Nasdaq: ANSV ... today announced that its consolidated financial statements for the ... Company,s annual report on Form 10-K filed with the ... a going concern qualification from its independent registered public ...
... notion that antiretrovirals can be postponed till later in ... HIV treatment before the patient,s immune system is too ... finds. , The finding may help settle a debate ... therapy can be deferred until later in the infection ...
... de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") ... Medicinas y Medicamentos Nacionales,S.A.P.I., de C.V., a Mexican company. ... Genomma Lab will sell new product lines,within the categories ... others. , Genomma Lab will ...
... Inc. (NYSE Alternext: ... treatment of wounds using Altrazeal(TM) Transforming Powder Dressing, and data ... at the annual APWCA National Clinical Conference in Philadelphia, April ... presentations and with posters on display during the meeting.Renaat Van ...
... LOCAL HEALTHCARE EXECUTIVE SPEAKS IN DALLAS ON THE PATIENT ... environment in which a patient heals is critical to ... Future must change to meet that need, said ... healthcare conference in Dallas last week.Rumore addressed the national ...
Cached Medicine News:Health News:Third sector gears up to meet 2Health News:Third sector gears up to meet 3Health News:Anesiva Announces Going Concern Opinion and Nasdaq Notice 2Health News:Anesiva Announces Going Concern Opinion and Nasdaq Notice 3Health News:Starting HIV Therapy Earlier Saves Lives 2Health News:Starting HIV Therapy Earlier Saves Lives 3Health News:Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 3Health News:'Patient Room of the Future' Speeds Healing 2
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
Medicine Products: